 |
1 Disease |  |
0 Trials |
|
0 Trials |  |
11 News |  |
- | Ancer-20 (Z-100) / Zeria Pharma
Journal: Potential of Z-100, extracted from Mycobacterium tuberculosis strain Aoyama B, as a hot tumor inducer. (Pubmed Central) - Dec 10, 2022
Furthermore, the antitumor effects of Z-100 were abolished in mice treated with an anti-CD8 antibody and in IL-12p40 KO mice. Thus, Z-100 induces its antitumor effects by increasing tumor-infiltrating CD8 T cells, suggesting that Z-100 may be a useful cancer therapy by acting as a hot tumor inducer.
- | Ancer-20 (Z-100) / Zeria Pharma
Journal: Peptidoglycan-Like Components in Z-100, Extracted from Mycobacterium tuberculosis Strain Aoyama B, Increase IL-12p40 via NOD2. (Pubmed Central) - Jul 6, 2022
Further, subcutaneous administration of Z-100 to mice significantly elevated expression of IL-12p40 and IL-1β and showed a trend towards increasing TNF-α in the skin. Z-100 induced the production of immunomodulatory cytokines from various types of macrophages and specifically increased IL-12p40 production through peptidoglycan-like components via NOD2.
- ||||| Ancer-20 (Z-100) / Zeria Pharma
Trial completion, Trial completion date, Metastases: Trial to Optimally Show the Pharmacological Action of Z-100 (clinicaltrials.gov) - Jun 16, 2022
P3, N=72, Completed, Sponsor: Zeria Pharmaceutical
Z-100 induced the production of immunomodulatory cytokines from various types of macrophages and specifically increased IL-12p40 production through peptidoglycan-like components via NOD2. Active, not recruiting --> Completed | Trial completion date: Oct 2022 --> Dec 2021
- ||||||| Ancer-20 (Z-100) / Zeria Pharma
Trial completion, Trial primary completion date, Metastases: Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer (clinicaltrials.gov) - Mar 4, 2022
P3, N=793, Completed, Sponsor: Zeria Pharmaceutical
Active, not recruiting --> Completed | Trial completion date: Oct 2022 --> Dec 2021 Active, not recruiting --> Completed | Trial primary completion date: Oct 2021 --> Jun 2021
- |||| Ancer-20 (Z-100) / Zeria Pharma
Enrollment closed, Metastases: Trial to Optimally Show the Pharmacological Action of Z-100 (clinicaltrials.gov) - Jul 2, 2019
P3, N=72, Active, not recruiting, Sponsor: Zeria Pharmaceutical
Active, not recruiting --> Completed | Trial primary completion date: Oct 2021 --> Jun 2021 Recruiting --> Active, not recruiting
- ||||| Ancer-20 (Z-100) / Zeria Pharma
Enrollment closed, Metastases: Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer (clinicaltrials.gov) - Jan 10, 2019
P3, N=780, Active, not recruiting, Sponsor: Zeria Pharmaceutical
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Ancer-20 (Z-100) / Zeria Pharma
Enrollment open, Metastases: Trial to Optimally Show the Pharmacological Action of Z-100 (clinicaltrials.gov) - Jul 12, 2018
P3, N=70, Recruiting, Sponsor: Zeria Pharmaceutical
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Ancer-20 (Z-100) / Zeria Pharma
Enrollment change, Metastases: Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer (clinicaltrials.gov) - Jun 6, 2018
P3, N=780, Recruiting, Sponsor: Zeria Pharmaceutical
Not yet recruiting --> Recruiting N=600 --> 780
- |||||||||| Ancer-20 (Z-100) / Zeria Pharma
New P3 trial, Metastases: Trial to Optimally Show the Pharmacological Action of Z-100 (clinicaltrials.gov) - Mar 22, 2018
P3, N=70, Not yet recruiting, Sponsor: Zeria Pharmaceutical
- |||||| Ancer-20 (Z-100) / Zeria Pharma
Enrollment open, Metastases: Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer (clinicaltrials.gov) - Dec 24, 2014
P3, N=600, Recruiting, Sponsor: Zeria Pharmaceutical
N=600 --> 780 Not yet recruiting --> Recruiting
- |||||||||| Ancer-20 (Z-100) / Zeria Pharma
New P3 trial, Metastases: Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer (clinicaltrials.gov) - Sep 28, 2014
P3, N=600, Not yet recruiting, Sponsor: Zeria Pharmaceutical